Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A detailed clinical guide to delayed-onset side effects of tesamorelin (Egrifta), including fluid retention, glucose changes, injection-site reactions, and IGF-1 elevation, with trial data, FDA labeling, and post-market evidence.
Read clinical reviewA data-driven breakdown of tesamorelin adverse event rates from Phase 3 trials, FDA labeling, FAERS reports, and post-market literature, reviewed by the HealthRX medical team.
Read clinical reviewA physician-reviewed guide to tesamorelin (Egrifta) side effects, including adverse events that may persist or become permanent, with data from clinical trials, the FDA label, and post-market surveillance.
Read clinical reviewA clinician-reviewed guide to the rare and serious adverse events associated with tesamorelin (Egrifta), including IGF-1 elevation, glucose dysregulation, malignancy risk, and injection-site reactions, with citations from trials and the FDA label.
Read clinical reviewA clinical breakdown of tesamorelin adverse events by severity grade and patient phenotype, drawing on Phase 3 trial data, FDA labeling, FAERS reports, and post-market literature.
Read clinical reviewA clinician-reviewed guide to tesamorelin withdrawal and discontinuation effects, covering visceral fat rebound, IGF-1 normalization, glucose changes, and how to taper or stop Egrifta safely.
Read clinical review